TY - JOUR
T1 - Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer
T2 - the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201
AU - Ninomiya, Kiichiro
AU - Hotta, Katsuyuki
AU - Hisamoto-Sato, Akiko
AU - Ichihara, Eiki
AU - Gotoda, Hiroko
AU - Morichika, Daisuke
AU - Tamura, Tomoki
AU - Kayatani, Hiroe
AU - Minami, Daisuke
AU - Kubo, Toshio
AU - Tabata, Masahiro
AU - Tanimoto, Mitsune
AU - Kiura, Katsuyuki
N1 - Publisher Copyright:
© 2015, Japan Society of Clinical Oncology.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Objective: We previously reported the feasibility of short-term low-volume hydration in patients with advanced lung cancer who received cisplatin-based chemotherapy (Jpn J Clin Oncol 2013). We sought to determine the clinical usefulness of a more convenient hydration method, evaluating the safety and efficacy of shorter-term and lower-volume hydration. Method: Chemonaïve patients with advanced lung cancer who were ≤75 years and reserved an adequate renal function for cisplatin use (≥60 mg/m2) were eligible. An intravenously administered hydration of 1700 ml in ~3.5 h with 1500 ml of orally administered hydration was investigated. The primary endpoint was the proportion of patients without grade 2 or worse renal toxicity in the first cycle. Results: A total of 45 patients were registered, all of whom were evaluable for renal toxicity. The median baseline creatinine score was 0.70 mg/dl, and the median cisplatin dose on day 1 was 75 mg/m2. In the first cycle, one patient (2 %) developed grade 2 creatinine toxicity, and thus, the proportion of patients with less than grade 2 was 98 % (the lower limit of 95 % confidence interval; 93 %), which met the primary endpoint. Five patients (11 %) had grade 1 or greater nephrotoxicity, three of whom successfully recovered. The objective response rate was 24 % and median progression-free survival 5.8 months. Conclusion: This prospective study demonstrated the safety and efficacy of shorter-term lower-volume hydration.
AB - Objective: We previously reported the feasibility of short-term low-volume hydration in patients with advanced lung cancer who received cisplatin-based chemotherapy (Jpn J Clin Oncol 2013). We sought to determine the clinical usefulness of a more convenient hydration method, evaluating the safety and efficacy of shorter-term and lower-volume hydration. Method: Chemonaïve patients with advanced lung cancer who were ≤75 years and reserved an adequate renal function for cisplatin use (≥60 mg/m2) were eligible. An intravenously administered hydration of 1700 ml in ~3.5 h with 1500 ml of orally administered hydration was investigated. The primary endpoint was the proportion of patients without grade 2 or worse renal toxicity in the first cycle. Results: A total of 45 patients were registered, all of whom were evaluable for renal toxicity. The median baseline creatinine score was 0.70 mg/dl, and the median cisplatin dose on day 1 was 75 mg/m2. In the first cycle, one patient (2 %) developed grade 2 creatinine toxicity, and thus, the proportion of patients with less than grade 2 was 98 % (the lower limit of 95 % confidence interval; 93 %), which met the primary endpoint. Five patients (11 %) had grade 1 or greater nephrotoxicity, three of whom successfully recovered. The objective response rate was 24 % and median progression-free survival 5.8 months. Conclusion: This prospective study demonstrated the safety and efficacy of shorter-term lower-volume hydration.
KW - Cisplatin
KW - Hydration
KW - Lung cancer
UR - http://www.scopus.com/inward/record.url?scp=84957964023&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957964023&partnerID=8YFLogxK
U2 - 10.1007/s10147-015-0860-1
DO - 10.1007/s10147-015-0860-1
M3 - Article
C2 - 26093520
AN - SCOPUS:84957964023
VL - 21
SP - 81
EP - 87
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
SN - 1341-9625
IS - 1
ER -